Clinical trials: Breast Density
Bone Density
ATAC - Bone Density Sub-Protocol
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.
- Trial name
- NCT00784940
- Testing
- Anastrozole, Tamoxifen
- Volunteers
- 308 people
- Sponsor
- AstraZeneca
Breast Neoplasms
MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue
Primary: In women with heterogeneous or dense breast tissue (mammographic types 3 and 4), MBI (Molecular Breast Imaging) will detect more breast cancers and have greater sensitivity in detecting breast cancer than breast…
- Trial name
- NCT02013726
- Testing
- MBI Scan: The LumaGEM®, 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Gamma Medica, Inc.
Breast Cancer, Breast Tumor Benign
Evaluation of Carebot AI MMG Medical Device for Breast Lesion Detection and Density Assessment
Comparison of accuracy of clinician and DLAD image evaluation (Carebot AI MMG v2.2) 1. Comparison of the Accuracy of Density Assessment by Clinician and DLAD (DENS) 2.
- Trial name
- EMBLEDDA-MMG (NCT06428799)
- Testing
- Carebot AI MMG
- Where
- 3 sites in Czechia
- Volunteers
- 122 people
- Sponsor
- Carebot s.r.o.
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Osteoporosis, Postmenopausal
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received…
- Trial name
- NCT00332709
- Testing
- Letrozole, Zoledronic acid
- Where
- 23 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Novartis
Breast Cancer
The ABC Study: Assessment of Breast Density Classification
The MARIA® breast imaging system is a CE-marked radiofrequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues.
- Trial name
- NCT04882306
- Testing
- Bilateral MARIA scan
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Micrima, Ltd.
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Mammographic Breast Density
Topical Endoxifen in Women
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change.
- Trial name
- CREME (NCT04616430)
- Testing
- Topical endoxifen
- Where
- Sweden
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Mammographic Density
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.
- Trial name
- NCT03264651
- Testing
- enobosarm
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Havah Therapeutics Pty Ltd
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and…
- Trial name
- NCT00333229
- Testing
- Zoledronic Acid
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Mammographic Breast Density
Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue
A study to determine the efficacy of 8 mg/day (4 mg/breast) of BHR-700 gel compared to placebo for reducing breast tissue density in women identified as having dense breast tissue upon analysis of screening mammography.
- Trial name
- 4WARD (NCT03199963)
- Testing
- 4-OH tamoxifen
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 223 people
- Sponsor
- BHR Pharma, LLC
Breast Cancer
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone…
- Trial name
- NCT00375505
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Breast Density
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density.
- Trial name
- NCT05068388
- Testing
- Z-Endoxifen
- Where
- Sweden
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Breast Cancer Detection, Dense Breast Parenchyma
Delphinus SoftVue™ ROC Reader Study
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in…
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening
- Trial name
- DMT SV RRS2 (NCT03972605)
- Testing
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Breast Cancer
CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study
To determine the impact on Interpreting Physician performance in detecting breast cancer, as defined by the area under the Receiver Operating Characteristic Curve (ROC), when Automated Breast Ultrasound (ABUS) and screening…
- Trial name
- NCT01424956
- Testing
- Automated Breast Ultrasound (ABUS)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- U-Systems, Inc.
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal…
- Trial name
- NCT00171704
- Testing
- Letrozole, Tamoxifen
- Where
- 13 sites in Denmark, United Kingdom
- Volunteers
- 263 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
Delphinus SoftVue Prospective Case Collection - ARM 2
The SoftVue™ is a whole breast ultrasound system with an automated scanning curvilinear ring-array transducer that employs UST. It is currently cleared under FDA 510(k) K123209 and K142517 for use as both a B-mode ultrasonic…
- Trial name
- SV PCC ARM2 (NCT02977247)
- Testing
- Non-Interventional, Automated Whole Breast Ultrasound
- Where
- 10 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Breast Cancer, Brain Metastases
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
- Trial name
- NCT02048059
- Testing
- ANG1005
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Angiochem Inc